A review of nateglinide in the management of patients with type 2 diabetes

References

• AbletshauserCBrunelPUsadelK-HEffect of nateglinide and glimepiride in reducing postprandial hyperglycemia in patients with type 2 diabetes mellitusBr J Diabetes Vasc Dis20055939
   Google Scholar
• AbrahamianHFrancesconiMLoiskandlAEvaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoringDiabetes Technol Ther2004631715000767
   PubMedGoogle Scholar
• American Diabetes AssociationPostprandial blood glucoseDiabetes Care200124775811315848
   PubMed Web of Science ®Google Scholar
• AkiyoshiMKakeiMNakazakiMA new hypoglycaemic agent, A-4166 inhibits ATP-sensitive potassium channels in rat pancreatic b-cellsAm J Physiol1995268E185E1937864093
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationReport of the Expert Committee on the Diagnosis and Classification of Diabetes MellitusDiabetes Care200528S37S4215618111
   PubMed Web of Science ®Google Scholar
• BallAJMcCluskeyJTFlattPRDrug-induced desensitization of insulinotropic actions of nateglinideBiochem Biophys Res Commun20002712343910777708
   PubMed Web of Science ®Google Scholar
• BallAJFlattPRMcClenaghanNHAcute and long-term effects of nateglinide on insulin secretory pathwaysBritish Journal of Pharmacology20041423677315155541
   PubMed Web of Science ®Google Scholar
• BarnettAHAndersonDMShelleySA placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycemia and hyperinsulinemia in patients with type 2 diabetesDiabetes Obes Metab200461041314746575
   PubMed Web of Science ®Google Scholar
• BlackCDonnellyPMcIntyreLMeglitinide analogues for type 2 diabetes mellitusCochrane Database Syst Rev200718CD00465417443551
   PubMedGoogle Scholar
• BokvistKHǿuMBushardKSelectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic a-cellsEur J Pharmacol19993861051110611470
   PubMed Web of Science ®Google Scholar
• BokvistKHǿuMPoulsenCRA4166, but not repaglinide, stimulate Ca2+-evoked KATP-channel independent secretion in rat pancreatic a- and b-cellsDiabetologia199841A139
   Web of Science ®Google Scholar
• Bratanova-TochkovaTKChengHDanielSTriggering and augmentation mechanisms, granule pools, and biphasic insulin secretionDiabetes200251S83S9011815463
   PubMed Web of Science ®Google Scholar
• CaliffRMHolmanRNavigator Trial Steering Committee and InvestigatorsPeople at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose toleranceJ Am Coll Cardiol200341Suppl A116951 Abstract
   Google Scholar
• CaputoSPitoccoDRuotoloVWhat is the real contribution of fasting plasma glucose and postprandial glucose in predicting HbA1c and overall blood glucose control?Diabetes Care200124201111679485
   PubMed Web of Science ®Google Scholar
• CarrollMFIzardARiboniKControl of postprandial hyperglycemia. Optimal use of short-acting insulin secretagoguesDiabetes Care20022521475212453952
   PubMed Web of Science ®Google Scholar
• CarrollMFGutierrezACastroMTargeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetesJ Clin Endocrinol Metab20038852485414602757
   PubMed Web of Science ®Google Scholar
• CerielloAQuagliaroLPiconiLEffect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatmentDiabetes2004537011014988255
   PubMed Web of Science ®Google Scholar
• CerielloAPostprandial hyperglycemia and diabetes complications: is it time to treat?Diabetes2005541715616004
   PubMed Web of Science ®Google Scholar
• ChachinMYamadaMFujitaANateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or a benzamido moiety, specifically inhibits pancreatic b-cell-type KATP channelsJ Pharmacol Exp Ther200330410253212604678
   PubMed Web of Science ®Google Scholar
• DashoraUKSibalLAshwellSGInsulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trialDiabet Med2007243444917298589
   PubMed Web of Science ®Google Scholar
• DaviesMJPost-prandial hyperglycaemia and prevention of cardiovascular diseaseDiabet Med200522121
   Web of Science ®Google Scholar
• DECODE Study GroupGlucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteriaLancet1999a35461721
   PubMed Web of Science ®Google Scholar
• DECODE Study GroupGlucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in EuropeLancet1999b35461721
   PubMed Web of Science ®Google Scholar
• DECODE Study Group, on behalf of the European Diabetes Epidemiology GroupGlucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteriaArch Intern Med200116139740411176766
   PubMed Web of Science ®Google Scholar
• DeFronzoRAPharmacologic therapy for type 2 diabetes mellitusAnn Intern Med200013373410877745
   PubMed Web of Science ®Google Scholar
• Del PratoSLoss of early insulin secretion leads to postprandial hyperglycemiaDiabetologia20034628
   PubMed Web of Science ®Google Scholar
• Del PratoSHeineRJKeilsonLTreatment of patients over 64 years of age with type 2 diabetes. Experience from nateglinide pooled database retrospective analysisDiabetes Care20032620758012832316
   PubMed Web of Science ®Google Scholar
• DimitriadisGBoutatiELambadiariVRestoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolismEur J Clin Invest200434490715255786
   PubMed Web of Science ®Google Scholar
• DinneenSFMechanism of postprandial hyperglycaemia in diabetes mellitusEur J Gastroenterol Hepatol19957724297496858
   PubMed Web of Science ®Google Scholar
• DornhorstAInsulinotropic meglitinide analoguesLancet2001358170911728565
   PubMed Web of Science ®Google Scholar
• DunnCFauldsDNateglinideDrugs2000606071511030470
   PubMed Web of Science ®Google Scholar
• European Diabetes Policy GroupA desktop guide to Type 2 diabetes mellitusDiabet Med1999167163010510947
   PubMed Web of Science ®Google Scholar
• FonsecaVClinical significance of targeting postprandial and fasting hyperglycaemia in managing type 2 diabetes mellitusCurr Med Res Opin2003196354114606987
   PubMed Web of Science ®Google Scholar
• FonsecaVGGrunbergerGSGuptaSAddition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic controlDiabetes Care20032616859012766094
   PubMed Web of Science ®Google Scholar
• FuchtenbuschMStandlESchatzHClinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitusExp Clin Endocrinol Diabetes20001081516310926309
   PubMed Web of Science ®Google Scholar
• GavinJRIIIPathophysiological mechanisms of postprandial hyperglycemiaAm J Cardiol2001884H8H
   PubMed Web of Science ®Google Scholar
• GerichJRaskinPJean-LouisLTwo-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metforminDiabetes Care2005282093916123472
   PubMed Web of Science ®Google Scholar
• GribbleFMManleySELevyJCRandomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166)Diabetes Care2001241221511423506
   PubMed Web of Science ®Google Scholar
• GromadaJBokvistKHǿuMNateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosisEur J Endocrinol20021471334212088930
   PubMed Web of Science ®Google Scholar
• HanefeldMBouterKPDickinsonSRapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemiaDiabetes Care200023202710868832
   PubMed Web of Science ®Google Scholar
• HansenAMChristensenITHansenJBDifferential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1Diabetes20025127899512196472
   PubMed Web of Science ®Google Scholar
• HazamaYMatsuhisaMOhtoshiKBeneficial effects of nateglinide on insulin resistance in type 2 diabetesDiabetes Res Clin Pract2006712515516214255
   PubMed Web of Science ®Google Scholar
• HiroseTMizunoRYoshimotoTThe effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin secretion by nateglinide in IGT subjectsEndocr J2002496495212625415
   PubMed Web of Science ®Google Scholar
• HollanderPSchwartzSLGatlinMRNateglinide, but not glyburide, selectively enhances early insulin release and more effectively controls post-meal glucose excursions with less total insulin exposureDiabetes200049Suppl 1A449 Abstract A449
   Google Scholar
• HollanderPASchwartzSLGatlinMRImportance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetesDiabetes Care200124983811375357
   PubMed Web of Science ®Google Scholar
• HomePContributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetesCurr Med Res Opin20051963541
   Google Scholar
• HortonEClinkingbeardCGatlinMNateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetesDiabetes Care2000231660511092289
   PubMed Web of Science ®Google Scholar
• HortonESFoleyJEShenSGEfficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetesCurr Med Res Opin200420883915200747
   PubMed Web of Science ®Google Scholar
• HuSWangSDunningBETissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta cell K (ATP) channelsJ Pharmacol Exp Ther19992911372910565863
   PubMed Web of Science ®Google Scholar
• HuSWangSFanelliBPancreatic b-cell KATP channel activity and membrane binding studies with nateglinide: a comparison with sulfonylureas and repaglinideJ Pharmacol Exp Ther20002934445210773014
   PubMed Web of Science ®Google Scholar
• HuSInteraction of nateglinide with K (ATP) channel in beta cells underlies its unique insulinotropic actionEur J Pharmacol20024421637112020694
   PubMed Web of Science ®Google Scholar
• KalbagJBWalterYHNedelmanJRMealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placeboDiabetes Care20012473711194245
   PubMed Web of Science ®Google Scholar
• KararaAHDunningBEMcLeodJFThe effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjectsJ Clin Pharmacol199939172911563410
   PubMed Web of Science ®Google Scholar
• KeilsonLMatherSWalterYHSynergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitusJ Clin Endocrinol Metab2000851081610720043
   PubMed Web of Science ®Google Scholar
• KhawKTWarehamNLubenRGlycated hemoglobin, diabetes and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk)BMJ2001322151811141143
   PubMed Web of Science ®Google Scholar
• LaferrèreBHeshkaSWangKIncretin levels and effect are markedly enhanced 1 month after roux-en-y gastric bypass surgery in obese patients with type 2 diabetesDiabetes Care20073017091617416796
   PubMed Web of Science ®Google Scholar
• LaghmichALadrièreLMalaisse-LagaeFLong-term effect of glibenclamide and nateglinide upon pancreatic islet cell function in normal and diabetic ratsPharmacol Res1999404758210660944
   PubMed Web of Science ®Google Scholar
• LeeWLCheungAMCapeDImpact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studiesDiabetes Care2000236928
   Web of Science ®Google Scholar
• LiJTianHLiQImprovement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients – a randomized controlled double-blind and double-dummy multicentre clinical trialDiabetes Obes Metab200795586517587398
   PubMed Web of Science ®Google Scholar
• LindholmLHIbsenHDahlofBCardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenololLancet200235910041011937179
   PubMed Web of Science ®Google Scholar
• LuzioSDAndersonDMOwensREffects of timing on administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjectsJ Clin Endocrinol Metab20018648748011600556
   PubMed Web of Science ®Google Scholar
• MaedlerKCarrRDBoscoDSulfonylurea induced beta-cell apoptosis in cultured human isletsJ Clin Endocrinol Metab200590501615483097
   PubMed Web of Science ®Google Scholar
• MalmbergKNorhammarAWedelHGlycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) studyCirculation19999926263210338454
   PubMed Web of Science ®Google Scholar
• MarreMVan GaalLUsadelKHNateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patientsDiabetes Obes Metab200241778612047396
   PubMed Web of Science ®Google Scholar
• MasumiATanakaAKyokoOFavourable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetesDiabetes Care200629118016644666
   PubMed Web of Science ®Google Scholar
• MazzoneTStrategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistanceAm J Cardiol200493112731
   Web of Science ®Google Scholar
• McClenaghanNHFlattPRPhysiological and pharmalogical regulation of insulin release: insights offered through exploitation of insulin-secreting cell linesDiab Obes Metab19991114
   Web of Science ®Google Scholar
• McLeodJFClinical pharmacokinetics of nateglinide: a rapidly absorbed, short-acting insulinotropic agentClin Pharmacokinet2004439712014748619
   PubMed Web of Science ®Google Scholar
• MineTMiuraKKitaharaYNateglinide suppresses postprandial hypertriglyceridemia in Zucker Fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamideBiol Pharm Bull2002251412612419950
   PubMed Web of Science ®Google Scholar
• MitrakouAKelleyDMokanMRole of reduced suppression of glucose production and diminished early insulin release in impaired glucose toleranceN Engl J Med19923262291727062
   PubMed Web of Science ®Google Scholar
• MonnierLColetteCMonnierLContributions of fasting and postprandial glucose to hemoglobin A1cEndocr Pract20061242616627379
   PubMedGoogle Scholar
• MoriYKuriyamaGTajimaNEffects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance testEndocrine200425203615758246
   PubMed Web of Science ®Google Scholar
• MosesRSlobodniukRBoyagesSEffect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care1999221192410333912
   PubMed Web of Science ®Google Scholar
• NakagamiTDECODE Study GroupHyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asia originDiabetologia2004473859414985967
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBManagement of Hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20062919637216873813
   PubMed Web of Science ®Google Scholar
• QuastUStephanDBiegerSThe impact of ATP sensitive K channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardiumDiabetes200453S156S16415561904
   PubMed Web of Science ®Google Scholar
• RaskinPKlaffLMcGillJRepaglinide vs Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metforminDiabetes Care2003262063812832314
   PubMed Web of Science ®Google Scholar
• ReavenGMBanting lecture. Role of insulin resistance in human diseaseDiabetes19883715956073056758
   PubMed Web of Science ®Google Scholar
• RisticSCollober-MaugeaisCPecherEComparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetes UKDiabet Med2006237576216842480
   PubMed Web of Science ®Google Scholar
• RosenstockJShenSGGatlinMRCombination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetesDiabetes Care20022515293312196422
   PubMed Web of Science ®Google Scholar
• SalorantaCHershonKBallMEfficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemiaJ Clin Endocrinol Metab2002874171612213867
   PubMed Web of Science ®Google Scholar
• ShibaTImprovement of insulin resistance by a new insulin secretagogue, nateglinide – analysis model based on the homeostasis modelDiabetes Res Clin Pract200362879414581145
   PubMed Web of Science ®Google Scholar
• ShimabukuroMHigaNTakasuNA single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patientsDiabet Med200421983615317602
   PubMed Web of Science ®Google Scholar
• SkrapariIPerreaDIoannidisIGlibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levelsDiabet Med200118781511678967
   PubMed Web of Science ®Google Scholar
• StandlEMarshallSMHomePDRizzaRANew drugs for diabetesThe Diabetes Annual199610AmsterdamElsevier22549
   Google Scholar
• StandlEBalletshoferBDahlBPredictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner ProjectDiabetologia199639154058960840
   PubMed Web of Science ®Google Scholar
• StandlEFuchtenbuschMThe role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type 2 diabetes mellitusDiabetologia200346306
   Google Scholar
• StandlESchnellOA new look at the heart in diabetes mellitus: from ailing to failingDiabetologia20004314556911151754
   PubMedGoogle Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ2000314051210938048
   PubMedGoogle Scholar
• StrawnWBChappellMCDeanRHInhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemiaCirculation200010115869310747353
   PubMed Web of Science ®Google Scholar
• TakesadaHMatsudaKOhtakeRStructure determination of metabolites isolated from urine and bile after administration of AY4166, a novel Dphenylalanine-derivative hypoglycemic agentBioorg and Med Chem199641771818931947
   PubMed Web of Science ®Google Scholar
• TenoSUtoYNagashimaHAssociation of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetesDiabetes Care2000231401610977041
   PubMed Web of Science ®Google Scholar
• TentolourisNBoutatiEKarambakalisNAcute Nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysisNutr Metab Cardiovasc Dis20051561215871845
   PubMed Web of Science ®Google Scholar
• TiinamijaTHonkanenEHIsomaaBImproved Prandial Glucose Control With Lower Risk of Hypoglycemia With Nateglinide Than With Glibenclamide in Patients With Maturity-Onset Diabetes of the Young Type 3Diabetes Care2006291899416443858
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group (UKPDS)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet1998352837539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group (UKPDS)Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)JAMA199928120051210359389
   PubMed Web of Science ®Google Scholar
• UtoYTenoSIwamotoYImprovement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretionMetabolism20025120411782867
   PubMed Web of Science ®Google Scholar
• Van den BergheGWoutersPWeekersFIntensive Insulin Therapy in Critically Ill PatientNEJM20013451913596711794168
   PubMed Web of Science ®Google Scholar
• VoytovichMHHaukereidCHjelmesaethJNateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipientsClin Transplant2007212465117425753
   PubMed Web of Science ®Google Scholar
• WardAJSalasMCaroJJHealth and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.KCost Eff Resour Alloc2004152215086954
   PubMedGoogle Scholar
• WeaverMLOrwigBARodriguezLCPharmacokinetics and metabolism of nateglinide in humansDrug Metab Dispos2001294152111259325
   PubMed Web of Science ®Google Scholar
• WeaverJURobertsonDAtkinSLOn behalf of The Nateglinide Glycaemic Control InvestigatorsNateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84Diabetes Obes Metab200263445215287927
   PubMed Web of Science ®Google Scholar
• WeyerCBogardusCMottDMThe natural history of insulin secretory dysfunction and resistance in the pathogenesis of type 2 diabetes mellitusJ Clin Invest19991047879410491414
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHComparisons of insulin regimes for patients with type 2 diabetesCurr Opin Endocr Diabet2000717583
   Google Scholar